GlassScriptPhysician profile
Andrew Eli Persits
NPI 1457678179
$5,914.55
in general payments reported to CMS, 2019-2025
22 companies · $1,007 in 2025
The $1,007 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $739 · 2020: $295 · 2021: $429 · 2022: $1,826 · 2023: $726 · 2024: $893 · 2025: $1,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,625.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,299.84 | 2019-2025 | Navitor, Mitraclip, Xience Sierra |
| Medtronic, INC. | $782.64 | 2023-2025 | Corevalve Evolut R, Symplicity G3, Onyx Frontier |
| Abiomed | $771.74 | 2022-2025 | Impella |
| Edwards Lifesciences Corporation | $346.20 | 2021-2025 | Sapien 3 Ultra Resilia |
| Medtronic Vascular, INC. | $283.71 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $209.76 | 2019-2020 | |
| Shockwave Medical, INC | $195.91 | 2025 | |
| Janssen Pharmaceuticals, INC | $145.52 | 2022-2024 | Xarelto |
| Penumbra, INC. | $141.47 | 2021-2025 | Indigo System |
| Amarin Pharma, INC. | $126.12 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2019 | |
| Atricure, INC. | $117.24 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $94.20 | 2023-2024 | Lifevest |
| Heartflow, INC. | $66.44 | 2023 | Ffrct |
| Cvrx, INC. | $44.00 | 2024 | Barostim Neo System |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $34.24 | 2025 | Amvuttra |
| Kiniksa Pharmaceuticals International, Plc | $27.72 | 2024 | Arcalyst |
| Boston Scientific Corporation | $24.98 | 2022 | |
| Chiesi USA, INC. | $23.13 | 2020 | |
| Stryker Corporation | $22.46 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Merck Sharp & Dohme LLC | $16.38 | 2024 | Verquvo |
| Teleflex LLC | $15.85 | 2025 | Chocolate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Persits listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.